For adults aged 70 and older who take statins to prevent a first heart attack or stroke but have no history of cardiovascular disease, stopping the medication appears generally safe in the short term, according to preliminary late-breaking research presented at the American Heart Association's Scientific Sessions 2026. The study, which included nearly 1,900 participants with multiple chronic conditions, found that after two years, those who discontinued statins had similar rates of heart attack, stroke, and death compared to those who continued. However, an extended follow-up of up to four years revealed a small but notable increase in cardiovascular events among those who stopped treatment.
The findings matter because they challenge the assumption that statins should be continued indefinitely for primary prevention in older adults, a group that often faces polypharmacy and potential side effects. About 25% of U.S. adults have high low-density lipoprotein-cholesterol (LDL-C), and statin therapy remains the foundation of lipid-lowering, as detailed in the Association's 2026 joint guideline on dyslipidemia. Yet the new study suggests that for older adults without existing cardiovascular disease, the benefits of continuing statins may diminish over time, while the risks of discontinuation may be lower than previously thought.
Lead author Rita F. Redberg, M.D., M.Sc., FAHA, professor of cardiology at the University of California, San Francisco School of Medicine, emphasized that the decision to stop should be individualized. "This small, increased risk of cardiovascular events means that one cannot make a general recommendation about stopping statins in this patient population," she said. "There should be shared decision-making between the patient and the healthcare professional." The study randomized 938 participants to discontinue statins and 942 to continue, tracking outcomes such as heart attack, stroke, death, quality of life, muscle pain, falls, and sarcopenia. At two years, there were no significant differences in any of these measures. But by four years, 12.7% of those who discontinued statins experienced a cardiovascular event or death, compared to 9.2% of those who continued.
The research, conducted at 24 clinical centers in Switzerland, France, and the Netherlands, is simultaneously published in The New England Journal of Medicine. While the findings are considered preliminary until peer review, they add to a growing body of evidence questioning the long-term use of statins in older adults. For patients and clinicians, the takeaway is clear: discontinuation is a reasonable option for some, but it requires careful discussion of individual risks and preferences. As Redberg noted, "In general, however, discontinuation is safe for most people who are in this age group and without a previous CVD event." For more information on cholesterol management, the American Heart Association provides resources on Cholesterol-Lowering Medications and Prevention and Treatment of High Cholesterol (Hyperlipidemia). The study's abstract is available in the 2026 Online Program Planner, and additional details can be found in the link to the news release.


